Current Atherosclerosis Reports

, Volume 5, Issue 2, pp 146–149 | Cite as

Myocardial infarction, stroke, and sudden cardiac death may be prevented by influenza vaccination

  • David G. Meyers


Acute myocardial infarction (AMI) and atherothrombotic stroke share a common pathogenesis involving disrupted atherosclerotic plaque and intravascular thrombosis. Both AMI and stroke have their peak incidence in winter months. Similarly, the incidence of upper respiratory infections (URIs), 38% of which are due to influenza, also peaks in winter (November and December). URIs result in many biochemical, cellular, and hemostatic changes that could predispose to plaque disruption and thrombosis. Infections, particularly URIs, frequently precede AMI and stroke. Up to 16% of persons older than 60 years of age experience a URI each year. Nineteen percent of those suffering an AMI recall a URI in the 2 weeks prior to their event. Three epidemiologic and one small clinical trial suggest that influenza vaccination is associated with a 50% reduction in incidence of sudden cardiac death, AMI, and ischemic stroke. Influenza vaccine is extremely safe and has a 50% efficacy. Theoretically, up to 104,500 AMIs and 192,000 nonembolic ischemic strokes could be prevented each year by influenza vaccination.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    American Heart Association: 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 2001.Google Scholar
  2. 2.
    Siscovick DS, Raghunathan TE, Lin D, et al.: Influenza vaccination and the risk of primary cardiac arrest. Am J Epidemiol 2000, 152: 674–677.PubMedCrossRefGoogle Scholar
  3. 3.
    Naghavi M, Barlas Z, Saidaty S, et al.: Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation 2000, 102: 3039–3045.PubMedGoogle Scholar
  4. 4.
    Lavallee P, Perchaud V, Gautier-Bertrand M, et al.: Association between influenza vaccination and reduced risk of brain infarction. Stroke 2002, 33: 513–518.PubMedCrossRefGoogle Scholar
  5. 5.
    Gurfinkle EP, Leon de la Fuente R, Mendiz O, Mautner B: Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions. The FLU Vaccination Acute Coronary Syndromes (FLUVACS) study. Circulation 2002, 105: 2143–2147.CrossRefGoogle Scholar
  6. 6.
    Libby P: Changing concepts of atherosclerosis. J Intern Med 2000, 247: 349–358.PubMedCrossRefGoogle Scholar
  7. 7.
    Shah PK: Plaque disruption and thrombosis. Cardiol Clin 1999, 17: 271–281.PubMedCrossRefGoogle Scholar
  8. 8.
    Zaman AG, Helft G, Worthley SG, Badimon JJ: The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 2000, 149: 251–266.PubMedCrossRefGoogle Scholar
  9. 9.
    Spencer FA, Goldberg RJ, Becker RC, Gore JM: Seasonal distribution of acute myocardial infarction in the second national registry of myocardial infarction. J Am Coll Cardiol 1998, 31: 1226–1233.PubMedCrossRefGoogle Scholar
  10. 10.
    Sheth T, Nair C, Muller J, Yusuf S: Increased winter mortality from acute myocardial infarction and stroke: the effect of age. J Am Coll Cardiol 1999, 33: 1916–1919.PubMedCrossRefGoogle Scholar
  11. 11.
    Jakovljevic D, Salomaa V, Sivenius J, et al.: Seasonal variation in the occurrence of stroke in the Finnish adult population. The FINMONICA Stroke Register. Stroke 1996, 27: 1774–1779.PubMedGoogle Scholar
  12. 12.
    Ku CS, Yang CY, Chiang HT, et al.: Absence of seasonal variation in myocardial infarction onset in a region without temperature extremes. Cardiology 1998, 89: 277–282.PubMedCrossRefGoogle Scholar
  13. 13.
    Monto AS, Sullivan KM: Acute respiratory illness in the community. Frequency of illness and the agents involved. Epidemiol Infect 1993, 110: 145–160.PubMedGoogle Scholar
  14. 14.
    Monto AS, Koopman JS, Bryan ER: The Tecumseh study of illness. XIV. Occurrence of respiratory viruses, 1976–1981. Am J Epidemiol 1986, 124: 359–367.PubMedGoogle Scholar
  15. 15.
    Kawahara J, Sano H, Fukuzaki H, et al.: Acute effects of exposure to cold on blood pressure, platelet function, and sympathetic nervous activity in humans. Am J Hypertens 1989, 2: 724–726.PubMedGoogle Scholar
  16. 16.
    Gordon DJ, Hydes J, Trost DC, et al.: Cyclic seasonal variation in plasma lipid and lipoprotein levels: the Lipid Research Clinics Coronary Primary Prevention Trial Placebo Control Group. J Clin Epidemiol 1988, 41: 679–689.PubMedCrossRefGoogle Scholar
  17. 17.
    Bull GM, Brozovic M, Chakrabarti R, et al.: Relationship of air temperature to various chemical, haematologic, and haemostatic variables. J Clin Pathol 1979, 32: 16–20.PubMedGoogle Scholar
  18. 18.
    Bussfeld D, Bacher M, Moritz A, et al.: Expression of transcription factor genes after influenza A virus infection. Immunobiology 1997, 198: 291–298.PubMedGoogle Scholar
  19. 19.
    Morrow DA, Ridker PM: C-reactive protein, inflammation, and coronary risk. Med Clin North Am 2000, 84: 149–161.PubMedCrossRefGoogle Scholar
  20. 20.
    Woodhouse PR, Khaw KT, Plummer M, et al.: Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and deaths from cardiovascular disease. Lancet 1994, 343: 435–439.PubMedCrossRefGoogle Scholar
  21. 21.
    Gronholdt ML, Dalager-Pederen S, Falk E: Coronary atherosclerosis: determinants of plaque rupture. Eur Heart J 1998, 19(suppl C): C24-C29.PubMedGoogle Scholar
  22. 22.
    Falk E, Shah PK, Fuster V: Coronary plaque disruption. Circulation 1995, 92: 657–671.PubMedGoogle Scholar
  23. 23.
    Visser MR, Tracy PB, Vercellotti GM, et al.: Enhanced thrombin generation and platelet binding on herpes simplex virus-infected endothelium. Proc Natl Acad Sci U S A 1988, 85: 8227–8230.PubMedCrossRefGoogle Scholar
  24. 24.
    Etingin OR, Silverstein RL, Hajjar DP: Von Willebrand factor mediates platelet adhesion to virally infected endothelial cells. Proc Natl Acad Sci U S A 1992, 90: 5153–5156.CrossRefGoogle Scholar
  25. 25.
    Key NS, Vercellotti GM, Winklemann JC, et al.: Infection of vascular endothelial cells with herpes simplex virus enhances tissue factor activity and reduces thrombomodulin expression. Proc Natl Acad Sci U S A 1990, 87: 7095–7099.PubMedCrossRefGoogle Scholar
  26. 26.
    van Dam-Mieras MC, Muller AD, van Hinsbergh VWM, et al.: The procoagulant response of cytomegalovirus infected endothelial cells. Thromb Haemost 1992, 68: 364–370.PubMedGoogle Scholar
  27. 27.
    Van Lenten BJ, Wagner AC, Navab M, Fogelman AM: Acute influenza A infection promotes increased macrophage infiltration into the artery wall that is prevented by apolipoprotein A-1. Circulation 2001, 104(suppl II):II-97.Google Scholar
  28. 28.
    Osler W: Diseases of the arteries. In Modern Medicine: Its Practice and Theory. Edited by Osler W. Philadelphia: Lea & Febiger; 1908:429–447.Google Scholar
  29. 29.
    Collins S: Excess mortality from causes other than influenza and pneumonia during influenza epidemics. Pub Health Rep 1932, 47: 2159–2179.Google Scholar
  30. 30.
    Gordon T, Thom T: The recent decrease in CHD mortality. Prev Med 1975, 4: 115–125.PubMedCrossRefGoogle Scholar
  31. 31.
    Pesonen E, Siitonen O: Acute myocardial infarction precipitated by infectious disease. Am Heart J 1981, 101: 512–513.PubMedCrossRefGoogle Scholar
  32. 32.
    Spodick DH, Flessas AP, Johnson MM: Association of acute respiratory symptoms with onset of acute myocardial infarction: prospective investigation of 150 consecutive patients and matched control patients. Am J Cardiol 1984, 53: 481–482.PubMedCrossRefGoogle Scholar
  33. 33.
    Meier CR, Jick SS, Derby LE, et al.: Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet 1998, 351: 1467–1471.PubMedCrossRefGoogle Scholar
  34. 34.
    Zheng ZJ, Mittleman MA, Tolfer GH, et al.: Infections prior to acute myocardial infarction onset [abstract]. J Am Coll Cardiol 1998, 31(suppl A):132A.Google Scholar
  35. 35.
    Pettinen J, Valonen P: The risk of myocardial infarction among Finnish farmers seeking medical care for an infection. Am J Pub Health 1996, 86: 1440–1442.Google Scholar
  36. 36.
    Gillum RF, Jacobs DR Jr, Luepker RV, et al.: Cardiovascular mortality trends in Minnesota, 1960-1978: the Minnesota Heart Survey. J Chronic Dis 1984, 37: 301–309.PubMedCrossRefGoogle Scholar
  37. 37.
    Zebrack JS, Anderson JL: The role of inflammation and infection in the pathogenesis and evolution of coronary artery disease. Curr Cardiol Rep 2002, 4: 278–288.PubMedCrossRefGoogle Scholar
  38. 38.
    Parchure N, Zouridokis EG, Kaski JC: Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation 2002, 105: 1298–1303.PubMedCrossRefGoogle Scholar
  39. 39.
    Wresli P, Czerwenka W, Meniconi A, et al.: Roxithromycin treatment of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men: a randomized double-blind placebo controlled trial. Circulation 2002, 105: 2646–2652.CrossRefGoogle Scholar
  40. 40.
    Hansson GK: Vaccination against atherosclerosis. Fact or fiction? Circulation 2002, 106: 1599–1601.PubMedCrossRefGoogle Scholar
  41. 41.
    Danesh J, Collins R, Peto R: Chronic infections and coronary heart disease: is there a link? Lancet 1997, 350: 430–436.PubMedCrossRefGoogle Scholar
  42. 42.
    Minick CR, Fabricant CG, Fabricant J, Litrenta MM: Atherosclerosis induced by infection with herpesvirus. Am J Pathol 1979, 96: 673–706.PubMedGoogle Scholar
  43. 43.
    Epstein SE: The multiple mechanisms by which infection may contribute to atherosclerosis development and course. Circ Res 2002, 91: 2–4.CrossRefGoogle Scholar
  44. 44.
    Gross PA, Hermogenes AW, Sacks HS, et al.: The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995, 123: 518–527.PubMedGoogle Scholar
  45. 45.
    Govaert TM, Thijs CT, Masurel N, et al.: The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994, 272: 1661–1665.PubMedCrossRefGoogle Scholar
  46. 46.
    Roacelli JD, Bass JW, Pang L: Guillain-Barre syndrome and influenza vaccination in the US Army, 1980–1988. Am J Epidemiol 1991, 133: 952–955.Google Scholar
  47. 47.
    Kasky T, Terracciano GL, Magder L, et al.: The Guillian-Barre syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N Engl J Med 1998, 339: 1797–1802.CrossRefGoogle Scholar
  48. 48.
    Nichol KL, Margolis KL, Lind A, et al.: Side effects associated with influenza vaccination in healthy working adults. Arch Intern Med 1996, 156: 1546–1550.PubMedCrossRefGoogle Scholar
  49. 49.
    Govaert TM, Dinant GJ, Aretz K, et al.: Adverse reactions to influenza vaccine in elderly people: randomized double blind placebo controlled trial. BMJ 1996, 307: 988–990.CrossRefGoogle Scholar
  50. 50.
    Centers for Disease Control and Prevention: Influenza and pneumococcal vaccination levels among persons aged >65 years—United States, 1999. MMWR 2001, 50: 532–537.Google Scholar

Copyright information

© Current Science Inc. 2003

Authors and Affiliations

  • David G. Meyers
    • 1
  1. 1.Division of Cardiovascular Diseases and Department of Preventive MedicineUniversity of Kansas School of MedicineKansas CityUSA

Personalised recommendations